A radical new understanding of what depression is and how it may be caused is helping us to quickly reverse the symptoms more effectively than ever before.
Discover a new therapy that can quickly reverse depression symptoms by lowering cortisol levels and neuroinflammatory activity while increasing neurotransmitter production, promoting new neuronal growth, and reconnecting vital brain centers that regulate mood and brain function.
Why RESTORE is better than ketamine The question of why RESTORE is better than ketamine seems like a simple one, but many factors need to be considered before making such an assessment. We will explore how and why the new RESTORE program offers significant advantages over typical methods for administering ketamine infusions in patients who Read More …
Resiliency: How to improve your mood and boost your immune response It’s hard to escape… Stress is all around us. Here’s how you can beat it Since the onset of COVID-19, we’ve all been inundated with strategies to keep us safe. By now, most of us have the hand-washing, mask-wearing, and social distancing habits down. Read More …
New Study Investigates Ketamine as A Potential Treatment for COVID-19 Ketamine may have a new role in combating the “cytokine storm” associated with serious Covid-19 infections. Ketamine, a safe and effective anesthetic medication developed in the 1960’s, well known for its ability to rapidly improve symptoms of depression, anxiety and PTSD is finding its way Read More …
NIMH Reports: Side Effects from Ketamine Infusion are Mild and Brief – Safety data analyzed from five NIH inpatient clinical trials Friday, November 15, 2019 National Institute of Mental Health Side effects mild, brief with single antidepressant dose of intravenous ketamine – Safety data analyzed from five NIH inpatient clinical trials One of the most Read More …
News: FDA’s Rapid Approval of Esketamine for Severe Depression Questioned Medscape News Pauline Anderson November 13, 2019 https://www.medscape.com/viewarticle/921248#vp_1 While some experts have hailed intranasal esketamine (Spravato, Janssen) as a “game changer” for treatment-resistant depression (TRD), others are concerned over the US Food and Drug Administration’s (FDA) rapid approval of the drug. In an editorial Read More …